Noetik
PrivateLast Round
Grant
Mar 5, 2025
Total Funding Raised
$54.25M
Company Overview
Noetik operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Grant round in March 2025.
Noetik is a biotechnology company that develops AI-driven platforms for cancer immunotherapy discovery and development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Data as a Service, Services & Consulting
AI Layer
Foundation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Noetik Comparables
Compare Noetik with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tahoe Therapeutics | 85% | |
| Bioptimus | 83% | |
| GenBio AI | 82% |
For institutional investors. Book with your work email.
Noetik Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 5, 2025 | ||||
| Series A | Aug 28, 2024 | ||||
| Seed | Sep 7, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Noetik Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Khosla Ventures | Series A |
| Zetta Venture Partners | Series A, Seed |
| The Roddenberry Foundation | Grant |
| Intermountain Ventures | Series A, Seed |
| Catalio Capital Management | Series A, Seed |
| EPIC Ventures | Series A, Seed |
| Breakout Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2025
Partnering with Agenus to develop predictive biomarkers for immuno-oncology.
- Apr 10, 2025
Dr. Emily Corse appointed EVP of Therapeutics.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenueAug 10, 2026
Noetik Inc. reaches $3.9M in revenue in September 2025.
For institutional investors. Book with your work email.
Noetik Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Noetik's valuation, stock price, and market status.
Is Noetik a public or private company?
Noetik is a private company.
What is the current stock price of Noetik?
Noetik is a private company, so its shares have no public market price. Caplight tracks Noetik's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Noetik worth (valuation)?
Valuation information for Noetik is not publicly available.
Can I buy Noetik stock?
Noetik shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Noetik's last funding round?
Noetik's most recent funding round was Grant on March 5, 2025.
Who are the main investors in Noetik?
Key investors in Noetik include Polaris Partners, DCVC (Data Collective).
Will Noetik IPO soon?
No public IPO plans have been announced for Noetik.
How can I track Noetik secondary market activity?
Caplight tracks bids, offers, and trades in Noetik's shares on secondary markets.